Cheers. Now as a newly listed company, there is not much out there in the public domain …to the extent that you can what is the number of shares outstanding (net and diluted) and from there any guidance on key financial metrics such as revenue, growth, EBITDA, etc …. Are you still expecting to release financials shortly?
Our fully-diluted share count as of the timing of the RTO transaction was 110,042,857 shares, and 21,134,533 of those are currently available to trade. We haven’t provided any forward-looking financial information publicly, but we expect we’ll be releasing our fourth-quarter and full-year 2018 results in late April and we’re looking forward to sharing more details on our financial performance and future expectations at that time.
OK …now, with so much going on at Vireo and the US industry itself I may have missed one or two key aspects of Vireo that current and prospective shareholders may be interested in … so this is your elevator pitch moment … is there anything you would like to add … why invest in Vireo?
I think we’ve covered a lot of ground so far, and I think it’s clear that we’re very excited about Vireo’s future. One thing that I think does get overlooked by the market today is that we are one of only nine other U.S. MSOs that has operations in 10 or more states, but we’ve been able to develop our footprint in an extremely cost-effective manner because of our scientific and medical expertise, and many of the long-term growth opportunities we’re pursuing are completely unique within the cannabis industry.
141